Asset
RESIQUIMOD SULFATE
EIKON THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06246110 | phase2 | active_not_recruiting | 2024-02-06 | 2026-12-01 | Eikon Therapeutics | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC |
| NCT07365319 | phase2_3 | recruiting | 2026-06-15 | 2035-12-31 | Eikon Therapeutics | A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. |
| NCT03486301 | phase1 | completed | 2018-02-15 | 2024-03-31 | Eikon Therapeutics | BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab |
| NCT04196530 | phase1 | completed | 2019-11-21 | 2024-07-31 | Eikon Therapeutics | BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab |
| NCT04819373 | phase2 | completed | 2021-08-30 | 2023-04-01 | Eikon Therapeutics | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.